Diabetes drug dapagliflozin could also be beneficial for patients with progressive liver disease, a clinical trial has shown.

Around 3,000 lives could be saved and 5,500 hospital admissions prevented each year by changes to how people are treated for heart failure, according to a watchdog. New draft guidelines from the ...

New guidelines for treating heart failure could save 3,000 lives and prevent 5,500 hospital admissions every year, according ...

A drug commonly used to treat type 2 diabetes may also help improve a serious liver condition, according to a new clinical ...

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and for improvement of fibrosis without worsening of MASH.

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type 2 diabetes, significantly improved liver inflammation and scarring in ...

Key Takeaways A diabetes drug can help treat fatty liver diseaseDapagliflozin helped lower fat levels and prevent scarring in ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...